Borden, Brittany A.
Lee, Sang Mee
Danahey, Keith
Galecki, Paige
Patrick-Miller, Linda
Siegler, Mark
Sorrentino, Matthew J.
Sacro, Yasmin
Davis, Andrew M.
Rubin, David T.
Lipstreuer, Kristen
Polonsky, Tamar S.
Nanda, Rita
Harper, William R.
Koyner, Jay L.
Burnet, Deborah L.
Stadler, Walter M.
Kavitt, Robert T.
Meltzer, David O.
Ratain, Mark J.
O’Donnell, Peter H.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5 U01 HL105198-09)
The Conquer Cancer Foundation for the American Society of Clinical Oncology
Article History
Received: 26 April 2018
Revised: 12 October 2018
Accepted: 21 December 2018
First Online: 4 February 2019
Compliance with ethical standards
:
: KD, MJR, and PHO are named as co-inventors on a pending patent application for the Genomic Prescribing System. MJR is a co-inventor holding patents related to pharmacogenetic diagnostics and receives royalties related to <i>UGT1A1</i> genotyping, although no royalties were received from the genotyping performed in this study. MJR work has been funded by the NIH, The Conquer Cancer Foundation of the American Society for Clinical Oncology, and The William F. O'Connor Foundation. PHO work has been funded by the NIH, The University of Chicago Comprehensive Cancer Center, The University of Chicago Bucksbaum Institute for Clinical Excellence, and the Central Society for Clinical and Translational Research. The remaining authors declare that they have no conflict of interest.